Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients

    TORONTO, Feb. 5 /CNW/ - Transition Therapeutics Inc. ("Transition" or the
"Company") (TSX: TTH, NASDAQ:  TTHI) today announced the completion of patient
enrolment for a Phase 2 clinical study of gastrin analogue, TT-223, in
patients with type 2 diabetes. The study is a randomized, double-blind,
placebo-controlled, dose-ranging study to evaluate the safety, tolerability
and efficacy of daily TT-223 treatments for 12 weeks with a 6-month follow-up.
Approximately 80 patients with type 2 diabetes have been enrolled in the
study. Patients receive a daily treatment of TT-223 in addition to their
current regimen of oral glucose lowering agents (metformin and/or

    About Gastrin-Based Therapies
    Transition and Eli Lilly and Company (NYSE:  LLY) have entered into a
licensing and collaboration agreement granting Lilly exclusive worldwide
rights to develop and commercialize gastrin based therapies, including the
lead compound TT-223. Gastrin based therapies are an emerging class of
potential disease-modifying therapies for patients with diabetes, and have
been shown to provide sustained improvement in glycemic control in preclinical
models and early clinical studies. Sustained improvement in glycemic control
is a key goal for patients with diabetes in order to alleviate the symptoms of
hyperglycemia and to prevent diabetic complications, and improving their
overall quality of life.

    About Transition
    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the
treatment of diabetes. Transition has an emerging pipeline of preclinical drug
candidates acquired externally and developed internally using its proprietary
drug discovery engine. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials. These
statements are based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include factors
beyond Transition's control and the risk factors and other cautionary
statements discussed in Transition's quarterly and annual filings with the
Canadian commissions.

    %SEDAR: 00015806E

For further information:

For further information: on Transition, visit or contact: Dr. Tony Cruz, Chief Executive
Officer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.223,; Elie Farah, President & Chief Financial
Officer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.203,; Transition Therapeutics Inc., 101 College
Street, Suite 220, Toronto, Ontario, M5G 1L7, Canada

Organization Profile

Transition Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890